To evaluate the association of bleeding with mortality in ST-elevation myocardial infarction (STEMI).
1 compared adjunctive anticoagulation with enoxaparin throughout the index hospitalization with unfractionated heparin (UFH) administered for 48 h in patients with ST-elevation myocardial infarction (STEMI) treated with fibrinolytic therapy. Enoxaparin was associated with a reduction in the primary composite of death and non-fatal MI (9.9 vs. 12.0%, P , 0.001), but an increase in major bleeding (2.1 vs. 1.4%, P , 0.001). There were no significant differences between enoxaparin and UFH in intracranial haemorrhage (ICH) (0.83 vs. 0.65%, P ¼ 0.14) or in mortality at 30 days (6.9 vs. 7.5%, P ¼ 0.11) or 1 year (10.5 vs. 10.6%, P ¼ 0.72). 2 Several studies have demonstrated an association between bleeding and mortality in patients with non-STE acute coronary syndromes (ACS) 3 -5 and STEMI. 6, 7 Efforts to reduce bleeding in patients with ACS are reflected in the development of safer antithrombotics, 8 alternative methods of arterial access, 9 enhancing haemostasis post-coronary angiography, 10 and the use of preventive therapies (e.g. proton-pump inhibitors to prevent gastrointestinal haemorrhage). However, the quantitative relationship, 6 causality, 11, 12 and impact of bleeding on late mortality 13, 14 remain uncertain and controversial. We undertook this analysis to ascertain the independent contribution of bleeding to mortality among patients enrolled in ExTRACT-TIMI 25, taking into account patient characteristics, treatments, and other cardiovascular complications.
Methods
Details of the ExTRACT-TIMI 25 trial have been published previously. 1, 15 In brief, this trial randomized 20 506 STEMI patients up to 6 h after the onset of symptoms for which fibrinolytic therapy was planned. Major exclusion criteria were: presence of cardiogenic shock, pericarditis, aortic dissection, contraindications to fibrinolysis, treatment with low-molecular weight heparin in the prior 8 h, known renal insufficiency [serum creatinine level .220 mmol/L (2.5 mg/dL) for men and .175 mmol/liter (2.0 mg/dL) for women], or life expectancy ,12 months. Patients were randomized 1:1 to either a strategy using enoxaparin or UFH in a double-dummy, double-blind fashion beginning between 15 min before and 30 min after the start of fibrinolysis. Enoxaparin was to be given as a 30 mg intravenous bolus followed by a subcutaneous injection of 1.0 mg/kg, with injections administered every 12 h. In patients aged 75 or older, the bolus dose was omitted and the maintenance dose reduced to 0.75 mg/kg. For patients with a creatinine clearance ,30 mL/min, the dose was 1.0 mg/kg every 24 h. The dose of UFH was 60 U/kg IV (maximum 4000 U) followed by an infusion of 12 U/kg/h (initial maximum 1000 U/h) with titration to achieve a target activated partial thromboplastin time of 1.5-2.0 times the control. The enoxaparin strategy was continued for 8 days or until hospital discharge (whichever came first), and UFH was continued for at least 48 h. We excluded patients who did not receive any anticoagulant study drug or fibrinolytic therapy, leaving 20 323 patients for analysis.
Bleeding definitions
Bleeding was defined using the TIMI scale as either major (ICH or overt bleeding resulting in a loss of haemoglobin .5 gm/dL adjusted for transfusion) or minor (overt bleeding resulting in a loss of haemoglobin of 3 -5 gm/dL adjusted for transfusion) 15 and assessed throughout the index hospitalization or Day 8 (which was also the maximum duration of the administration of study drug), whichever came first. If a patient had multiple bleeding events, we assigned them the bleeding event of highest severity in the following order: (1) ICH; (2) non-ICH major; and (3) TIMI minor bleeding.
Endpoints
The primary endpoint of interest in this analysis was all-cause mortality through 30 days. The secondary endpoint was 1-year mortality. A landmark analysis explored mortality between Days 30 and 365 among patients who survived to Day 30, by calculating the conditional probability of an event given no events were observed in the first 30 days. The cause of death, bleeding severity, and location were adjudicated by a blinded, independent clinical endpoint committee.
Statistical models
Multivariate Cox models predicting mortality were constructed in a stepwise fashion adding covariates from the five groups below to construct a final model that included all statistically significant variables from each of the five steps. In each step, we used backward elimination, requiring a multivariate P , 0.05 for retention in the model. Variables with .5% missing data were not considered as candidate variables.
(1) Most severe type of bleeding during the index hospitalization (up to 8 days maximum). (2) Patient characteristics at randomization, including age, sex, race, diabetes; history of hypertension, angina, MI, or percutaneous coronary intervention (PCI); current smoking, Killip class, systolic blood pressure, heart rate, location of MI, presence of left bundle branch block, time from symptom onset to fibrinolytic. 
Results
Among 20 323 subjects in the ExTRACT-TIMI 25 trial, 309 (1.5%) had a TIMI major bleeding event during the index hospitalization. Of these, 143 (0.70%) suffered an ICH and 166 (0.82%) a non-ICH TIMI major bleeding event. There were 386 (1.9%) patients who had TIMI minor bleeding without TIMI major bleeding, and 19 628 (96.6%) with no TIMI major or minor bleeding during the index hospitalization. Patient characteristics according to the type of in-hospital bleeding are summarized in Table 1 . Patients with bleeding (compared with those with no bleeding) during the index hospitalization were more likely to be older, female, a non-smoker, with lower body weight, and higher TIMI risk score. 17 These same factors were also more prevalent in patients with ICH compared with patients with non-ICH major bleeding, with the exception of low body weight. Prior use of aspirin or non-steroidal anti-inflammatory drugs and post-randomization enoxaparin were more prevalent among patients with in-hospital bleeding events, whereas patients with ICH had higher systolic blood pressure and were more likely to have been treated with a fibrin-specific lytic. Relations between bleeding and outcomes in STEMI patients
Mortality through 30 days
The all-cause mortality rates through 30 days were 37.6% among patients with TIMI major bleeding during the index hospitalization compared with 9.8% for those with TIMI minor bleeding and 6.6% for those without TIMI major or minor bleeding (P , 0.001) ( Figure 1A) . The 30-day mortality rates were 65.4 and 13.9% among those with ICH and non-ICH major bleeds, respectively (P , 0.001) ( Figure 1B) . Sequential adjustment for baseline characteristics, medical therapies, and invasive procedures reduced the HR for patients with ICH and for patients with non-ICH major bleeding, but both remained statistically significant (both P , 0.001, Table 2 ). Additional adjustment for cardiovascular events during the index hospitalization revealed an important confounding relationship between the development of cardiogenic shock during hospitalization and non-ICH major bleeding. This was further explored in models that grouped patients according to the presence or absence of cardiogenic shock and non-ICH major bleeding and the order of these two events if both were present. Patients Figure 1 The 30-day all-cause mortality in patients with and without bleeding (A) and by the type of major bleeding (B). Bleeding events during the index hospitalization were used to classify patients as major, minor, or no bleeding (A) and as intracranial haemorrhage, non-intracranial haemorrhage, and no bleeding (B). See text and Cardiogenic shock, ischaemic stroke, and severe heart failure. who had a non-ICH major bleed either in the absence of cardiogenic shock, or prior to cardiogenic shock, did not exhibit a significantly increased risk of mortality at 30 days (HR 1.3, P ¼ 0.68; HR 2.5, P ¼ 0.24, respectively). In contrast, patients who developed cardiogenic shock prior to discharge but did not have a major non-ICH bleed (HR 19.6), and patients developing cardiogenic shock before a non-ICH major bleed (HR 16.1) had a substantial increase in risk in 30-day mortality (P , 0.001 for both). In the fully adjusted model predicting 30-day mortality, the HR for ICH was 10.3 (8.2 -12.8). However, neither non-ICH major bleeding nor minor bleeding was a statistically significant predictor of death from Days 5 to 30 ( Table 2 ) after adjustment for intercurrent hospital clinical events, particularly cardiogenic shock and MI. In a Cox model, the three most important variables contributing to 30-day mortality were development of cardiogenic shock prior to discharge, increased age, and ICH ( Table 3 ). The per cent of information content that each variable contributed to the model estimated by the likelihood ratios were 61, 17 (per decade), and 7.8%, for these three variables, respectively. Neither non-ICH major bleeding nor minor bleeding contributed significantly to the model (contributions 0.22 and 0.03%, respectively).
These findings were supported by a comparison of the causes of death among patients who died by Day 30, stratified by the type of bleeding during the index hospitalization. Intracranial haemorrhage was listed as the cause in 80/93 of deaths at 30 days among patients with an ICH prior to discharge. However, among the 23 patients with a non-ICH major bleed who died by Day 30, the most common cause of death was congestive heart failure/shock (n ¼ 9), and only 6 deaths were attributed to bleeding. In the 38 patients with a minor bleed who died by Day 30, non-haemorrhagic cardiovascular causes accounted for 32 deaths, whereas non-ICH bleeding was classified as the cause of death in only 3 patients.
Mortality at 1 year
Mortality at 1 year was 42.9% among patients with major bleeding and 9.9% among those without bleeding (P , 0.001). However, the mortality rate was most marked among those with ICH (71.8%), whereas mortality rates were 18.1 and 15.8% among patients with non-ICH major and minor bleeding, respectively (unadjusted P-values vs. no bleeding ≤0.001 for each). After multivariate adjustment, only ICH remained independently associated with increased mortality at 1 year (HR 8.7, P , 0.001), contributing 5.9% to the fully adjusted model. Cardiogenic shock during the index hospitalization (HR 10.6, contribution 52%) and age (HR 1.6 per decade, contribution 23%) were the most important correlates of 1-year mortality. Non-ICH major bleeding and minor bleeding each contributed ≤0.2% to the model.
Landmark analyses of deaths between Days 31 and 365
Among the patients who survived to Day 30, there were 192 patients (1.0%) with a TIMI major bleeding event [including 49 (0.26%) with ICH and 143 (0.76%) with non-ICH major bleeding] and 348 (1.8%) with a minor bleeding event during the index hospitalization. The 18 318 patients (97.1%) with no major bleeding during the index hospitalization and who survived to Day 30 served as the comparator group. Mortality rates between Days 31 and 365 among survivors to Day 30 were 8.5% among patients with major bleeding, 6.6% in those with minor bleeding, and 3.5% among those without bleeding (P , 0.001 for major bleeding and P ¼ 0.002 for minor bleeding compared with no bleeding) ( Figure 2A) . However, the excess in mortality between Days 31 and 365 among patients with major bleeding during the index hospitalization compared with those with no bleeding was driven by a high mortality rate between Days 30 and 365 among patients with an initial ICH who had survived the first 30 days (18.5%, P , 0.001 compared with patients with no bleeding). There were no significant differences in mortality at 31-365 days in patients with an in-hospital non-ICH major bleed (5.0%) compared with those with no bleeding (3.5%, unadjusted P ¼ 0.36) ( Figure 2B) .
In analyses adjusted for baseline characteristics (Table 4) , the HR for ICH remained statistically significant (4.6, P , 0.001), but was attenuated compared with the unadjusted analysis (HR 5.8). Moreover, after adjustment for baseline characteristics, there were no significant associations between either non-ICH major bleeding or minor bleeding and mortality between Days 31 and 365 ( Table 4) . The most important baseline characteristics that confounded the relationship between non-ICH bleeding and later mortality included age (HR 1.6 per decade), heart rate (HR 1.2 per 10 b.p.m. increase), Killip class . I (HR 1.5), time from symptom onset to fibrinolytic (HR 1.1 per additional hour delay), systolic blood pressure (HR 1.1 per each 10 mmHg lower), prior angina (HR 1.4), prior MI (HR 1.5), and diabetes (HR 1.4) (P ≤ 0.001 for each). In the fully adjusted Cox model, the variables that most strongly contributed to mortality between Days 31 and 365 were age (HR 1.6 per each decade, contribution 43%) and heart rate (HR 1.2 per 10 b.p.m. increase, contribution 18%). adjusted for baseline patient characteristics, medications, and predischarge invasive procedures (P ≤ 0.001). Re-infarction (HR 1.9 (1.3 -2.7), P , 0.001), but neither non-ICH major bleeding (HR 1.0 (0.6 -1.7), P ¼ 0.99) nor minor bleeding (HR 1.2 (0.8 -1.7), P ¼ 0.46), remained independently associated with mortality between Days 5 and 30 after adjustment for cardiovascular events, including cardiogenic shock. In the landmark analysis exploring death between 31 and 365 days among survivors to Day 30, the HRs for re-infarction were 1.5 (P ¼ 0.087) with and 1.5 (P ¼ 0.055) without cardiogenic shock in the model.
Relationship of recurrent myocardial infarction and non-intracranial haemorrhage bleeding with mortality

Discussion
The major findings of these analyses of the relationship between major bleeding and mortality during the index hospitalization of 20 323 patients with STEMI enrolled in a worldwide fibrinolytic trial include the following. Our findings underscore the poor prognosis associated with ICH, a complication of fibrinolytic therapy in patients with STEMI that persists despite the development of drugs with increased fibrin specificity and a reduction in the dosing of concomitant anticoagulant. 18 Our observations with regard to non-ICH bleeding are consistent with the report by Spencer et al. 6 which demonstrated that patient comorbidity accounts for an important part of the excess mortality in patients with major bleeding following MI. In fact, in the landmark analysis, the unadjusted mortality rates from Days 31 to 365 among survivors to Day 30 shows a higher mortality for patients with an in-hospital minor bleeding (6.6%) compared with non-ICH major bleeding (5.0%), an observation that is no longer present once adjustment is made for differences in baseline characteristics. Our analyses suggest that early deaths following non-ICH major bleeding are related to antecedent cardiovascular events (particularly cardiogenic shock). Early deaths following minor bleeding and deaths after 30 days in patients with either non-ICH major or minor bleeding are largely explained by the higher risk profile of these patients as determined by their baseline characteristics. Our results differ from some prior analyses 3, 5, 7 of the relationship between bleeding and death due to important differences in the analytic techniques used, study populations (STEMI vs. non-STE ACS), and treatments administered (fibrinolytic vs. primary PCI or no reperfusion therapy). To minimize the biases and confounding that can arise in such analyses, we evaluated ICH and non-ICH bleeding separately, included invasive procedures, in-hospital cardiovascular events, and the timing of these events in our adjusted models, and performed landmark analyses to provide greater insight into the relationship between in-hospital bleeding and short-and long-term mortalities.
A number of studies, particularly from contemporary trials of newer anti-thrombotic agents in patients with non-STE ACS, have advanced the hypothesis that less bleeding translates into lower mortality. 3, 5, 7 This hypothesis is attractive since reducing bleeding is ispso facto a desirable outcome. Thus, a reduction in bleeding, if it truly were causally related to a reduction in mortality, would represent an important additional benefit to patients. These notions have led to new recommendations in the European Society of Cardiology Clinical Practice Guidelines in Patients with Non-STE-ACS highlighting the importance of assessing the risk of bleeding and initiating steps (and therapies) to minimize bleeding. 11 In addition, bleeding often results in blood transfusion, which itself has been associated with poorer outcomes 19, 20 in some, but not all, 21, 22 analyses. Therefore, reducing bleeding is an important goal in the development of future therapies. The relationship between bleeding and ischaemic events is not straightforward. 23 First, bleeding complications represent a postrandomization event, and by nature, any comparison of patients with vs. without bleeding (the so-called 'endpoint -endpoint' analysis) runs a substantial risk of confounding due to imbalance between the groups (i.e. one cannot randomize patients to 'bleeding' vs. 'no bleeding'). 24 Differences in baseline characteristics, therapies (before and after randomization), and timing of events among patients with and without a bleeding event may be marked. 6 Second, despite attempts to adjust for various differences between groups of patients with vs. without bleeding, retrospective analyses are not able to capture all relevant covariates, including many that may have led physicians to recommend for or against specific procedures and treatments which could have affected outcomes, including bleeding. Third, determining the causal relationship between post-randomization events, such as bleeding and mortality, may be confounded by other events that may occur before (e.g. cardiogenic shock), coincident (e.g. surgery), or after (e.g. transfusion) the bleeding event. Modelling the effects of individual events that are part of a complex, inter-related web is difficult to accomplish using standard multivariate techniques. Furthermore, assigning the cause of death to a single (or the most proximate) event may not adequately describe the subtleties involved. For example, bleeding may cause ischaemia due to a mismatch in oxygen supply demand, which may then lead to a fatal arrhythmia. Additional research and alternative methods to assess the possible causal relationship between bleeding, concurrent events, and mortality are needed. We have recently adopted efforts in our adjudication of death in ongoing clinical trials to provide greater granularity regarding the presence and possible causal relationship between bleeding and death by asking the clinical endpoint committee to determine, in each patient who dies and had a bleeding event, whether the bleeding was fatal, contributed to the cause of death, or was unrelated to death.
Limitations
Our findings represent a post-hoc analysis of patients classified by an event (bleeding) that occurred after randomization through discharge or Day 8 in a clinical trial of patients with STEMI treated with fibrinolytic and antithrombin. The ExTRACT-TIMI 25 trial was not prospectively designed to analyse the relationship between bleeding and mortality, and the frequency of some clinical events were low, thus limiting our power to detect differences between subgroups of patients. Thus, our observations are exploratory in nature, and as such should be considered to be hypothesis-generating. We utilized multivariate techniques to adjust for potential confounders, but cannot exclude the possibility that additional unmeasured confounders influenced the outcomes. Strict enrollment criteria were used to identify patients eligible for enrollment in ExTRACT-TIMI 25, patient management was guided by a study protocol, and the TIMI criteria were used to classify bleeding. We and others have implemented efforts to include multiple bleeding scales in ongoing trials to facilitate future analyses of bleeding within and across studies. All of our patients were treated with a fibrinolytic and either enoxaparin or UFH during the index hospitalization for a maximum of 8 days, and bleeding data were not systematically reported beyond discharge/Day 8. Therefore, the findings described above may not apply to all patients with STEMI or those with NSTE-ACS in clinical practice.
Conclusions
Intracranial haemorrhage, but not non-ICH TIMI major or minor bleeding, is strongly associated with short (30-day) and longerterm (1-year) mortality in patients undergoing fibrinolysis for STEMI. In addition to ICH, development of cardiogenic shock during the index hospitalization and advanced age are important contributors to mortality both at 30 days and 1 year. Thus, efforts to reduce mortality after STEMI should focus on prevention of pump failure and intracranial bleeding. Non-ICH bleeding following fibrinolytic therapy is associated with excess mortality, and further efforts to reduce these bleeding events are desirable. However, the relationship between non-ICH bleeding and mortality is complex and highly confounded. Neither non-ICH TIMI major nor minor bleeding was independently associated with an increase in either short-or longer-term mortality once patient baseline characteristics, treatments, and concurrent cardiovascular events were taken into consideration.
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